During the recent session, Psyence Biomedical Ltd (NASDAQ:PBM)’s traded shares were 0.68 million, with the beta value of the company hitting 0.19. At the last check today, the stock’s price was $5.53, reflecting an intraday gain of 6.04% or $0.31. The 52-week high for the PBM share is $699.19, that puts it down -12543.58 from that peak though still a striking 47.2% gain since the share price plummeted to a 52-week low of $2.92. The company’s market capitalization is $3.22M, and the average intraday trading volume over the past 10 days was 0.2 million shares, and the average trade volume was 65.19K shares over the past three months.

Psyence Biomedical Ltd (NASDAQ:PBM) trade information

Psyence Biomedical Ltd (PBM) registered a 6.04% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.04% in intraday trading to $5.53, hitting a weekly high. The stock’s 5-day price performance is 25.23%, and it has moved by 52.16% in 30 days. Based on these gigs, the overall price performance for the year is -98.85%. The short interest in Psyence Biomedical Ltd (NASDAQ:PBM) is 34037.0 shares and it means that shorts have 0.45 day(s) to cover.

PBM Dividends

Psyence Biomedical Ltd is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Psyence Biomedical Ltd (NASDAQ:PBM)’s Major holders

Psyence Biomedical Ltd insiders own 0.59% of total outstanding shares while institutional holders control 13.61%, with the float percentage being 13.69%.

Data provided on Apr 30, 2025 indicates that AdvisorShares Trust-AdvisorShares Psychedelics ETF owns about 4.45 shares. This amounts to just over 0.76 percent of the company’s overall shares, with a $23045.0 market value.